Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
AssigneeCalifornia Institute of Technology
InventorsPaul H. Patterson, Ronit Lahav
Life of this patent
Estimating the term…
Abstract
Described herein are results which show that an endothelin receptor antagonist, BQ788, increases pigmentation and significantly reduces the viability of 7 human melanoma cell lines in culture. Moreover, it is described herein that administration of BQ788 significantly slows melanoma tumor growth in nude mice, including a complete growth arrest in half of the mice treated systemically. Thus, inhibitors of endothelin receptor activity are described herein as beneficial for the treatment of cancer.
Claims16
A method of treating cancer comprising:
- administering to an individual in need of treatment for cancer, a selective inhibitor of an endothelin-B receptor activity, in a therapeutically effective amount.
A method for reducing abnormal proliferation of a cell comprising an endothelin B-receptor, said method comprising administering an inhibitor to an endothelin B-receptor to said cell in an amount for reducing proliferation.
A method for inducing differentiation in a cell comprising an endothelin B-receptor, said method comprising administering an inhibitor to an endothelin B-receptor to said cell in an amount for inducing differentiation.
A method for inducing apoptosis in a cell comprising an endothelin B-receptor, said method comprising administering an inhibitor to an endothelin B-receptor to said cell in an amount for inducing apoptosis.
A method for delivering a substance to a cancerous cell in an individual comprising:
- conjugating a substance to BQ788 or a derivative thereof which is functionally equivalent to form a conjugate;
- and
- administering said conjugate to said individual.
Dependencies are inferred from the claim text.